Skip to content

Comparison of Two Strategies for Surfactant Prophylaxis in Premature Infants

A Randomized Trial: Comparison of Two Strategies for Surfactant Prophylaxis in Premature Infants

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01294852
Enrollment
100
Registered
2011-02-14
Start date
2010-01-31
Completion date
2012-06-30
Last updated
2011-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Birth, Premature Lungs

Keywords

prophylactic, surfactant, premature, mechanical ventilation, mortality, morbidities

Brief summary

The purpose of this study is to determine whether the immediate bolus strategy combined with early nasal CPAP (nCPAP) treatment could decrease the subsequent need for ventilation compared to the administration of surfactant prophylaxis at 15 minutes after birth with early nCPAP in premature infants.

Detailed description

Respiratory distress syndrome (RDS) is a syndrome in premature infants caused by developmental insufficiency of surfactant production and structural immaturity in the lungs. Exogenous surfactant therapy has become well established in newborn infants with RDS. Surfactant replacement therapy, either as a rescue treatment or a prophylactic, reduces mortality and several aspects of morbidity in babies with RDS. It is known that infants who are at a significant risk of RDS should receive prophylactic surfactant therapy, but the optimal timing and strategy for prophylactic surfactant therapy remains controversial. When administered immediately after delivery, surfactant mixes with the fetal lung fluid and reaches the alveoli before the onset of lung injury potentially created by the first applied positive pressure ventilation. As another approach, surfactant prophylaxis may be administered after resuscitation and stabilization.

Interventions

OTHERsurfactant prophylaxis

Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]).

Sponsors

Ankara University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
1 Minutes to 2 Years
Healthy volunteers
No

Inclusion criteria

* Premature infants born before 28 weeks' gestation * Premature infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery

Exclusion criteria

* Infants died at delivery room

Design outcomes

Primary

MeasureTime frameDescription
ventilatory requirementwithin the first 5 days of lifeInfants with RDS may require mechanical ventilation. Mechinal ventilation causes volu- and barotrauma in the lungs and associated morbidities. The earlier surfactant is given, the better it works. So immediate surfactant prophylaxis given before the first breath may decrease the requirement for mechanical ventilation compared with surfactant prophylaxis given at 15 minutes of age after resuscitation and stabilization.

Secondary

MeasureTime frame
Pulmonary hemorrhagefirst 72 hours of life
patent ductus arteriosusfirst one week
necrotizing enterocolitisfirst one month
retinopathy of prematurityfirst two months
Pneumothoraxfirst 72 hours of life
bronchopulmonary dysplasiafirst two months
duration of hospitalizationone year
mortalityone year
intraventricular hemorrhagefirst one week

Countries

Turkey (Türkiye)

Contacts

Primary ContactSaadet Arsan, Professor
Saadet.Arsan@medicine.ankara.edu.tr90 312 5956390
Backup ContactEmel Okulu, MD
emelderelli@hotmail.com90 312 5956390

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026